Forma Therapeutics, a biopharmaceutical company, and the Experimental Therapeutics Centre of Singapore, have signed a collaboration agreement to leverage Forma’s transformative chemistry platform to discover novel compounds for further development by ETC.
The Experimental Therapeutics Centre of Singapore (ETC) is funded by the Agency for Science, Technology & Research of Singapore, which is committed to fostering scientific research and talent for a knowledge-based Singapore. Financial terms were not disclosed.
Steven Tregay, CEO of Forma, said: Working collaboratively with ETC will allow us to demonstrate the power of Forma’s transformative chemistry platform across a broad range of targets pursued by ETC. We share a commitment to advancing early-stage science and translating those discoveries into practical clinical applications.
This collaboration is therefore mutually beneficial, potentially bolstering Singapore’s biomedical pipeline of the future, while also further validating the productivity and efficiency of Forma’s drug discovery technologies in identifying new, promising compounds.
Forma Therapeutics is a biopharmaceutical company leverages drug discovery platform to address challenging targets and develop a robust internal pipeline of oncology drugs.
The Experimental Therapeutics Centre focuses on the gap between basic and applied biomedical research. ETC engages in early stage drug discovery and development, to developing research tools for clinical analysis, as well as setting up public-private partnerships to facilitate the advancement of drug candidates.